Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design-Reference-Cited by-同舟云学术

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Published:2022-04 Issue:10336 Volume:399 Page:1695-1707
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Fizazi Karim,Foulon Stéphanie,Carles Joan,Roubaud Guilhem,McDermott Ray,Fléchon Aude,Tombal Bertrand,Supiot Stéphane,Berthold Dominik,Ronchin Philippe,Kacso Gabriel,Gravis Gwenaëlle,Calabro Fabio,Berdah Jean-François,Hasbini Ali,Silva Marlon,Thiery-Vuillemin Antoine,Latorzeff Igor,Mourey Loïc,Laguerre Brigitte,Abadie-Lacourtoisie Sophie,Martin Etienne,El Kouri Claude,Escande Anne,Rosello Alvar,Magne Nicolas,Schlurmann Friederike,Priou Frank,Chand-Fouche Marie-Eve,Freixa Salvador Villà,Jamaluddin Muhammad,Rieger Isabelle,Bossi Alberto

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial;Gravis;Lancet Oncol,2013

2. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial;James;Lancet,2016

4. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED Trial;Kyriakopoulos;J Clin Oncol,2018

5. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial;Clarke;Ann Oncol,2019

Cited by 371 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis;Clinical Genitourinary Cancer;2024-12

2. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

3. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors;Clinical Genitourinary Cancer;2024-10

4. Documento de consenso internacional sobre la integridad de los ensayos clínicos;Medicina de Familia. SEMERGEN;2024-10

5. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10